Duke logo

BMS-817 (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if Nivolumab and Ipilimumab will work for treating lung cancer with high tumor mutation burden.

What is the Condition Being Studied?

Non-small cell lung cancer (NSCLC)

Who Can Participate in the Study?

Adults who have lung cancer (first-line non-small cell lung cancer) with high tumor mutation burden (TMB)

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get nivolumab 240 mg every 2 weeks and ipilimumab at 1 mg/kg every 6 weeks as long as you are getting better

Study Details

Full Title
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in participants with Non-Small Cell Lung Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00075721
NCT:NCT02869789
Phase
Phase IV
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698